Cocrystal Pharma Secures $5M Private Placement from OPKO Health, Extending Cash Runway
COCP is trading near its 52-week low of $0.76 (11% above the low).
Summary
Cocrystal Pharma raised $5 million in a private placement from related party OPKO Health at $0.9134 per share — a premium to the current price. The funding addresses an urgent cash need ahead of pivotal norovirus trial data later this year.
Key Events · Financing and Capital Events · COCP
-
$5M Private Placement to OPKO Health
Cocrystal sold 5,474,053 shares at $0.9134 per share to OPKO Health, a longtime investor and related party, for gross proceeds of $5.0 million. The price represents a premium to the current $0.8463 market price.
-
Related-Party Transaction
OPKO Health CEO Dr. Phillip Frost is Cocrystal's co-founder, director, and principal stockholder. The investment signals insider conviction but also raises governance considerations.
-
No Warrants or Derivatives
The transaction was a straight common stock sale with no warrants or other derivative securities, avoiding the dilutive and potentially toxic terms common in distressed biotech financings.
-
Funding Extends Runway to Key Catalyst
Proceeds will fund preclinical and clinical programs, including the lead norovirus candidate CDI-988. Topline Phase 1b data is expected by the end of Q4 2026, a critical value inflection point.
Analysis · COCP · Life Sciences
With a going-concern warning and less than 12 months of cash on hand, Cocrystal Pharma secured $5 million from longtime investor OPKO Health at $0.9134 per share — a slight premium to the current $0.8463 price. The deal is a related-party transaction: OPKO CEO Dr. Phillip Frost is Cocrystal's co-founder, director, and principal stockholder. Notably, no warrants or derivatives were included, sidestepping the toxic terms often seen in distressed biotech financings. The capital extends the runway as the company approaches a critical catalyst — Phase 1b norovirus data expected by end of 2026.
At the time of this filing, COCP was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.3M. The 52-week trading range was $0.76 to $2.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.